ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "comparative effectiveness"

  • Abstract Number: 2412 • ACR Convergence 2023

    Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice

    María del Carmen San José Méndez1, Uxía Couto Lareo1, Vanesa Balboa Barreiro2, Francisco J. Blanco1, Bruno de aspe de la iglesia1, Antonio Atanes Sandoval3, Diego Dios Santos1, Jesús Carlos Fernández López1, Mercedes Freire González1, Guillermo González Arribas1, Genaro Graña Gil1, Natividad Oreiro Villar1, Jose Antonio Pinto Tasende1, Francisco Javier De Toro Santos1, Clara Ventin Rodriguez1, Maite silva díaz3 and Ana Lois Iglesias1, 1Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 2Clinic epidemiology and biostatistics department. Complejo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 3Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain

    Background/Purpose: Giant cell arteritis (GCA) affects large and medium size arteries. Biopsy was considered the gold standard in the diagnosis1, but in the last years…
  • Abstract Number: 2485 • ACR Convergence 2023

    Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

    April Jorge1, Baijun Zhou1, Yuqing Zhang2 and Hyon K. Choi3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: In randomized placebo-controlled trials, including the phase 4 Belimumab Assessment of Safety in SLE study, belimumab use was associated with a higher incidence of…
  • Abstract Number: 0155 • ACR Convergence 2023

    Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis

    Aniket Kawatkar, David Yi, Erika Estrada and Cecilia Portugal, Kaiser Permanente Southern California, Pasadena, CA

    Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…
  • Abstract Number: 2529 • ACR Convergence 2023

    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Jeffrey R Curtis1, Tarun Arora2, Ye Liu3, Vanessa C. Brunetti4, Tzu-Chieh Lin4, Leslie Spangler4, Robert K. Stad4, Michele McDermott4, Brian D. Bradbury4 and Min Kim4, 1Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
  • Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium

    Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

    Cagri Yildirim-Toruner1, Daniel Glaser2, Timothy Beukelman3, Stacy Ardoin4, Ahmar Hashmi5, Rajdeep Pooni6, Maria Fernandez5, Vincent Del Gaizo7, Leslie Hanrahan7, Mary Ellen Riordan8, Stacey Tarvin9 and CARRA Registry Investigators7, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Yale University School of Medicine, New Haven, CT, 3University of Alabama at Birmingham, Birmingham, AL, 4Nationwide Children's Hospital, Columbus, OH, 5The University of Texas Health Sciences Center at Houston, Institute for Implementation Science, Houston, TX, 6Stanford University, Palo Alto, CA, 7CARRA, Washington, DC, 8Hackensack Meridian Health/ Joseph M. Sanzari Children's Hospital, Hackensack, NJ, 9Riley Hospital for Children at Indiana University Health, Indianapolis, IN

    Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…
  • Abstract Number: 0058 • ACR Convergence 2022

    Health System Improvement in Inpatient ANA and Serologic Test Utilization

    Saloni Goyal1, Yasin kanakrieh1, Marie O'Brien1, Amy Slenker1, Kathryn Zaffiri1 and James Ross2, 1Lehigh Valley Health Network, Allentown, PA, 2lvhn, Macungie, PA

    Background/Purpose: In 2005 Lehigh Valley Health Network (LVHN) instituted order sets for ANA serologic reflex testing with the objective to facilitate more efficient patient work-up…
  • Abstract Number: 0133 • ACR Convergence 2022

    Retention Rate of Targeted Therapies in Erdheim-Chester Disease

    Corrado Campochiaro1, alessandro tomelleri1, Francesco Pegoraro2, Giovanni Galardi3, Nicola Farina4, Martina Mazzariol5, Francesco Catamerò6, Giacomo De Luca4, Giulio Cavalli4, Augusto Vaglio7 and Lorenzo Dagna8, 1IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, 2Department of Health Sciences, University of Florence, Firenze, Italy, 3Department of Health Sciences, University of Florence, Florence, Italy, 4IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Milano, Italy, 5University of Turin, Torino, Italy, 6Vita-Salute San Raffaele University, Milano, Italy, 7Azienda Ospedaliero Universitaria Meyer, Parna, Italy, 8IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Italy

    Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last…
  • Abstract Number: 0576 • ACR Convergence 2022

    Comparative Effectiveness of Osteoporosis (OP) Therapies Among a Population of Postmenopausal (PM) Women in the United States (U.S.)

    Min Kim1, Leah J McGrath2, David Pritchard2, Peter Samai2, Jay Lin1, Robert Kees Stad3, Leslie Spangler1, Michele McDermott1, Brian D Bradbury4 and M Alan Brookhart2, 1Amgen, Inc., Thousand Oaks, CA, 2NoviSci, Inc., Durham, NC, 3Amgen Inc., Zug, Switzerland, 4Amgen Inc., 1 Amgen Center Drive

    Background/Purpose: Although clinical trials evaluating the efficacy of osteoporosis (OP) therapies have shown that denosumab (Dmab) significantly increases bone mineral density at pivotal sites compared…
  • Abstract Number: 0714 • ACR Convergence 2022

    Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis

    Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Serostatus may be associated with different responses to treatment with biologic disease-modifying anti-rheumatic drugs (DMARD) or Janus kinase inhibitors (JAKi) in patients with rheumatoid…
  • Abstract Number: 0934 • ACR Convergence 2022

    Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

    Jun Won Park1, Min Jung Kim2, Hyoun-Ah Kim3, Jinhyun Kim4, Eun Bong Lee1 and Kichul Shin5, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, 3Ajou University School of Medicine, Suwon, Republic of Korea, 4Chungnam National University Hospital, Jung-gu, Daejeon, South Korea, 5Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea

    Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
  • Abstract Number: 1084 • ACR Convergence 2022

    Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study

    Xavier Puéchal1, Michele Iudici2, Elodie Perrodeau3, bernard bonnotte4, Francois Lifermann5, Thomas Le Gallou6, Alexandre Karras7, Claire Blanchard-Delaunay8, Thomas Quéméneur9, Achille Aouba10, Olivier Aumaître11, Vincent Cottin12, Mohamed Hamidou13, Marc Ruivard11, Pascal Cohen1, Luc Mouthon1, Loïc Guillevin1, Philippe Ravaud3, Raphaël Porcher3 and Benjamin Terrier1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 3Université Paris Cité, Hôtel-Dieu, Paris, France, 4Centre Hospitalo-Universitaire de Dijon, Dijon, France, 5Dax Hospital, Dax, France, 6Rennes Sud University Hospital, Rennes, France, 7HEGP, Paris, France, 8Niort Hospital, Niort, France, 9Valenciennes Hospital, Valenciennes, France, 10Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 11Clermont Ferrand University Hospital, Clermont-Ferrand, France, 12Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 13Nantes University Hospital, Nantes, France

    Background/Purpose: Randomized controlled trials showed rituximab (RTX)'s non-inferiority to cyclophosphamide (CYC) for induction therapy of ANCA-associated vasculitis and neither treatment was favoured in granulomatosis with…
  • Abstract Number: 1430 • ACR Convergence 2022

    Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis

    Cristiano Moura1, Luck Lukusa1, Laura Yan1, Walter P Maksymowych2, Denis Choquette3, Gilles Boire4 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada

    Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
  • Abstract Number: 1432 • ACR Convergence 2022

    Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects

    Anna Dryja1, Anna Lucia Buccarello2, Isabelle Gaillard2 and Joëlle Monnet2, 1MTZ Clinical Research Sp. z o.o.,, Warsaw, Poland, 2Fresenius Kabi Swiss BioSim, Eysins, Switzerland

    Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…
  • Abstract Number: 1669 • ACR Convergence 2022

    Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis

    Anne Bass1, Noha Abdel-Wahab2, Pankti Reid3, Jeffrey Sparks4, Cassandra Calabrese5, Deanna Jannat-Khah, DrPH, MSPH6, Diviya Rajesh6, Nilasha Ghosh6, Komal Mushtaq7, Farah Al Haj8, Adewunmi Falohun9, Lydia Gedmintas10, Lindsey MacFarlane11, Senada Arabelovic11, Adi Diab2, Ami Shah12, Clifton O. Bingham III13, Karmela Kim Chan6 and Laura C. Cappelli14, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2UT MD Anderson Cancer Center, Houston, TX, 3University of Chicago Medical Center, Chicago, IL, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Cleveland Clinic Foundation, Cleveland Heights, OH, 6Hospital for Special Surgery, New York, NY, 7Cleveland Clinic, Cleveland, OH, 8Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, 9MD Anderson Cancer Center, Houston, TX, 10Brigham and Women's Hospital, Boston, MA, 11Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 12Johns Hopkins Rheumatology, Baltimore, MD, 13Johns Hopkins University, Baltimore, MD, 14Johns Hopkins School of Medicine, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
  • Abstract Number: 1679 • ACR Convergence 2022

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes

    Yukiko Kimura1, Sarah Ringold2, George Tomlinson3, Laura Schanberg4, Anne Dennos5, MaryEllen Riordan6, Vincent Del Gaizo7, Katherine Murphy8, Pamela Weiss9, Brian Feldman10, Mei Sing Ong11 and Marc Natter12, 1Hackensack Meridian Health, New York, NY, 2Janssen, Seattle, WA, 3University of Toronto, Toronto, ON, Canada, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Hackensack Meridian Health, Hackensack, NJ, 7CARRA, Inc, Washington, DC, 8CARRA, Inc, New Orleans, LA, 9Children's Hospital of Philadelphia, Glen Mills, PA, 10Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 11Harvard Pilgrim Institute, Boston, MA, 12Boston Children's Hospital, Boston, MA

    Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology